One blood draw, 
Ultra-high-fidelity results

Two tubes of blood

Access precision care through
a simple blood draw

How Guardant360 works

How Guardant360 Works Icon - One

Submit two tubes of blood

How Guardant360 Works Icon - One

Our proprietary digital sequencing method enhances sensitivity and specificity

How Guardant360 Works Icon - One

We look for actionable somatic alterations across solid tumor sites

How Guardant360 Works Icon - One

Doctors get clear and accurate results within two weeks

How Guardant360 Works Icon - One

Guardant Access manages billing and provides financial support

What a Guardant360 report looks like

Patient Information and Tumor Response Map

Indication of the serial testing report number and status
Additional recipient field added to share and collaborate with
Guardant Tumor Response Map
Tumor Heterogeneity
– Each Color: a mutation across all tumor sites
–Color Height: relative % cfDNA in blood
Tumor Evolution
– Outer Shape: patient disease burden across test points
Change in Color
– Height: tumor clonality across test points
Summary of detected alterations for most recent test date
Identify alterations associated with lack of response to a therapy
Case Studies Diagram

Alteration and Therapy List

Alterations arranged by % cfDNA by gene
Quickly identify alterations associated with therapies
Therapies associated with alteration
Clinical trials associated with alteration; nearby sites highlighted
Alteration-specific trendline Detected on current report Non-detected on current report Detected on past report Non-detected on past report
Explanation of variants with unknown significance
Enhanced Provider Portal: Interact with the Tumor Response Map and other report sections
Case Studies Diagram

Access Guardant360 results any time through
our HIPAA-compliant portal

View individual reports and a complete practice summary

Safely share patient records with consulting physicians

Explore the clinical and biological relevance of genes and variants

See all therapy options including clinical trials

How do we achieve high specificity?

NGS zoom icon

We search for tumor-DNA fragments among billions of cells

NGS zoom icon

We digitally tag each DNA fragment and make millions of copies

NGS zoom icon

Standard sequencing methods introduce errors and false positives

NGS zoom icon

Our digital inference engine reduces these errors by 1000x

Our proprietary digital sequencing technology lets us identify the signal of your patient's individual genomic alterations from the noise of interfering data that is inherent to standard next-generation sequencing techniques.

Common Questions

What are genomic alterations and why are they important to cancer?

Genomic alterations are changes that occur within the DNA of cancer cells. Some of these changes accelerate the growth of cancer. Some respond well to specific therapies. With a clear picture of the genomic alterations in your tumor, your doctor may be able to recommend a targeted therapy. In general, targeted therapies have fewer side effects than broad-based chemotherapy. They can also be more selective in stopping the spread of a cancer when other treatments have failed.

How can knowing my cancer's genomic alterations help my treatment?

Some genomic alterations are known to respond better to specific therapies. Guardant360 looks for all these clinically relevant alterations, giving your doctor the opportunity to tailor treatment to your individual cancer.

How quickly can I expect test results?

We provide results within 2 weeks of receiving your blood sample.

Does it matter what type of cancer I have or how advanced my cancer is?

Yes. Guardant360 is only indicated for advanced solid tumors. It does not test for hematological cancers like leukemia, nor early stage disease.

Does Guardant360 predict response to chemotherapy? Can it tell me how my cancer will progress?

Today Guardant360 does not predict chemotherapy response, but it does provide information on the genomic alterations known to respond to specific targeted therapies. As cancer research progresses, new response profiles may be identified.